Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT03970447 2026-04-08

GBM AGILE

Phase 2/3 Recruiting

2,250 enrolled

CNS

Glioblastoma, Recurrence

NCT03315364 2026-04-01

OPTIMAL

Phase 2/3 Active not recruiting

549 enrolled

Breast

Breast Neoplasms, Recurrence

NCT07502118 2026-03-30

NexCAR19

Phase 2/3 Recruiting

40 enrolled

Lymphoid

Cytokine Release Syndrome, Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02491632 2026-03-18

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

Phase 2/3 Active not recruiting

90 enrolled 13 charts

Fatigue, Neoplasm Metastasis, Neoplasms, Recurrence

NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

Phase 2/3 Active not recruiting

70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

NCT07366801 2026-01-26

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Phase 2/3 Recruiting

64 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 2/3 Active not recruiting

289 enrolled 35 charts 2 FDA

Myeloid

Myelodysplastic Syndromes, Recurrence

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Phase 2/3 Active not recruiting

110 enrolled

Delirium, Neoplasm Metastasis, Recurrence

NCT04442022 2025-10-03

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2/3 Recruiting

501 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07198451 2025-09-30

GEM-IR-NMIBC

Phase 2/3 Not yet recruiting

320 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Recurrence

Clinical Trials

AHEAD-MERIT

GBM AGILE

OPTIMAL

NexCAR19

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

GEM-IR-NMIBC